Research ArticleArticle
Development of Quality Indicators for an Integrated Approach of Knee Osteoarthritis
Lies Grypdonck, Bert Aertgeerts, Frank Luyten, Hub Wollersheim, Johan Bellemans, Koen Peers, Sabine Verschueren, Patrik Vankrunkelsven and Rosella Hermens
The Journal of Rheumatology April 2014, jrheum.130680; DOI: https://doi.org/10.3899/jrheum.130680
Lies Grypdonck
From the Academic Center for General Practice, KU Leuven, Leuven; Division of Rheumatology, University Hospitals Leuven, Leuven, Belgium; IQ Healthcare, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; Division of Orthopedics and Traumatology, Department of Development and Regeneration, University Hospitals Leuven; Physical Medicine and Rehabilitation, University Hospitals Leuven, Pellenberg; and Department of Rehabilitation Sciences, KU Leuven, Heverlee, Belgium. J. Bellemans has previously received institutional support from Smith and Nephew, Biomet, Zimmer, Sanofi Aventis, Technische Orthopedie Belgie, and Pfizer; G. Claes has been involved in studies sponsored by Bayer, Pfizer, BMS, Sanofi-Aventis, ThromboGenics, and Smith-Nephew; and is a former or current member of the advisory boards of Bayer, Pfizer, and Sanofi-Aventis. L. Grypdonck, MD; B. Aertgeerts, MD, PhD, Academic Center for General Practice, KU Leuven; F. Luyten, MD, PhD, Division of Rheumatology, University Hospitals Leuven; H. Wollersheim, MD, PhD, Academic Center for General Practice, KU Leuven; IQ Healthcare, Radboud University Nijmegen Medical Centre; J. Bellemans, MD, PhD, Division of Orthopedics and Traumatology, Department of Development and Regeneration, University Hospitals Leuven; K. Peers, MD, PhD, Physical Medicine and Rehabilitation, University Hospitals Leuven; S. Verschueren, PT, PhD, Department of Rehabilitation Sciences, KU Leuven; P. Vankrunkelsven, MD, PhD, Academic Center for General Practice, KU Leuven; R. Hermens, PhD, Academic Center for General Practice, KU Leuven and IQ Healthcare, Radboud University Nijmegen Medical Centre. Address correspondence to Dr. L. Grypdonck, Academic Center for General Practice, KU Leuven, Kapucijnenvoer 33, blok J, 3000 Leuven, Belgium. E-mail: lies.grypdonck@med.kuleuven.be. Accepted for publication January 11, 2014.
Bert Aertgeerts
From the Academic Center for General Practice, KU Leuven, Leuven; Division of Rheumatology, University Hospitals Leuven, Leuven, Belgium; IQ Healthcare, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; Division of Orthopedics and Traumatology, Department of Development and Regeneration, University Hospitals Leuven; Physical Medicine and Rehabilitation, University Hospitals Leuven, Pellenberg; and Department of Rehabilitation Sciences, KU Leuven, Heverlee, Belgium. J. Bellemans has previously received institutional support from Smith and Nephew, Biomet, Zimmer, Sanofi Aventis, Technische Orthopedie Belgie, and Pfizer; G. Claes has been involved in studies sponsored by Bayer, Pfizer, BMS, Sanofi-Aventis, ThromboGenics, and Smith-Nephew; and is a former or current member of the advisory boards of Bayer, Pfizer, and Sanofi-Aventis. L. Grypdonck, MD; B. Aertgeerts, MD, PhD, Academic Center for General Practice, KU Leuven; F. Luyten, MD, PhD, Division of Rheumatology, University Hospitals Leuven; H. Wollersheim, MD, PhD, Academic Center for General Practice, KU Leuven; IQ Healthcare, Radboud University Nijmegen Medical Centre; J. Bellemans, MD, PhD, Division of Orthopedics and Traumatology, Department of Development and Regeneration, University Hospitals Leuven; K. Peers, MD, PhD, Physical Medicine and Rehabilitation, University Hospitals Leuven; S. Verschueren, PT, PhD, Department of Rehabilitation Sciences, KU Leuven; P. Vankrunkelsven, MD, PhD, Academic Center for General Practice, KU Leuven; R. Hermens, PhD, Academic Center for General Practice, KU Leuven and IQ Healthcare, Radboud University Nijmegen Medical Centre. Address correspondence to Dr. L. Grypdonck, Academic Center for General Practice, KU Leuven, Kapucijnenvoer 33, blok J, 3000 Leuven, Belgium. E-mail: lies.grypdonck@med.kuleuven.be. Accepted for publication January 11, 2014.
Frank Luyten
From the Academic Center for General Practice, KU Leuven, Leuven; Division of Rheumatology, University Hospitals Leuven, Leuven, Belgium; IQ Healthcare, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; Division of Orthopedics and Traumatology, Department of Development and Regeneration, University Hospitals Leuven; Physical Medicine and Rehabilitation, University Hospitals Leuven, Pellenberg; and Department of Rehabilitation Sciences, KU Leuven, Heverlee, Belgium. J. Bellemans has previously received institutional support from Smith and Nephew, Biomet, Zimmer, Sanofi Aventis, Technische Orthopedie Belgie, and Pfizer; G. Claes has been involved in studies sponsored by Bayer, Pfizer, BMS, Sanofi-Aventis, ThromboGenics, and Smith-Nephew; and is a former or current member of the advisory boards of Bayer, Pfizer, and Sanofi-Aventis. L. Grypdonck, MD; B. Aertgeerts, MD, PhD, Academic Center for General Practice, KU Leuven; F. Luyten, MD, PhD, Division of Rheumatology, University Hospitals Leuven; H. Wollersheim, MD, PhD, Academic Center for General Practice, KU Leuven; IQ Healthcare, Radboud University Nijmegen Medical Centre; J. Bellemans, MD, PhD, Division of Orthopedics and Traumatology, Department of Development and Regeneration, University Hospitals Leuven; K. Peers, MD, PhD, Physical Medicine and Rehabilitation, University Hospitals Leuven; S. Verschueren, PT, PhD, Department of Rehabilitation Sciences, KU Leuven; P. Vankrunkelsven, MD, PhD, Academic Center for General Practice, KU Leuven; R. Hermens, PhD, Academic Center for General Practice, KU Leuven and IQ Healthcare, Radboud University Nijmegen Medical Centre. Address correspondence to Dr. L. Grypdonck, Academic Center for General Practice, KU Leuven, Kapucijnenvoer 33, blok J, 3000 Leuven, Belgium. E-mail: lies.grypdonck@med.kuleuven.be. Accepted for publication January 11, 2014.
Hub Wollersheim
From the Academic Center for General Practice, KU Leuven, Leuven; Division of Rheumatology, University Hospitals Leuven, Leuven, Belgium; IQ Healthcare, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; Division of Orthopedics and Traumatology, Department of Development and Regeneration, University Hospitals Leuven; Physical Medicine and Rehabilitation, University Hospitals Leuven, Pellenberg; and Department of Rehabilitation Sciences, KU Leuven, Heverlee, Belgium. J. Bellemans has previously received institutional support from Smith and Nephew, Biomet, Zimmer, Sanofi Aventis, Technische Orthopedie Belgie, and Pfizer; G. Claes has been involved in studies sponsored by Bayer, Pfizer, BMS, Sanofi-Aventis, ThromboGenics, and Smith-Nephew; and is a former or current member of the advisory boards of Bayer, Pfizer, and Sanofi-Aventis. L. Grypdonck, MD; B. Aertgeerts, MD, PhD, Academic Center for General Practice, KU Leuven; F. Luyten, MD, PhD, Division of Rheumatology, University Hospitals Leuven; H. Wollersheim, MD, PhD, Academic Center for General Practice, KU Leuven; IQ Healthcare, Radboud University Nijmegen Medical Centre; J. Bellemans, MD, PhD, Division of Orthopedics and Traumatology, Department of Development and Regeneration, University Hospitals Leuven; K. Peers, MD, PhD, Physical Medicine and Rehabilitation, University Hospitals Leuven; S. Verschueren, PT, PhD, Department of Rehabilitation Sciences, KU Leuven; P. Vankrunkelsven, MD, PhD, Academic Center for General Practice, KU Leuven; R. Hermens, PhD, Academic Center for General Practice, KU Leuven and IQ Healthcare, Radboud University Nijmegen Medical Centre. Address correspondence to Dr. L. Grypdonck, Academic Center for General Practice, KU Leuven, Kapucijnenvoer 33, blok J, 3000 Leuven, Belgium. E-mail: lies.grypdonck@med.kuleuven.be. Accepted for publication January 11, 2014.
Johan Bellemans
From the Academic Center for General Practice, KU Leuven, Leuven; Division of Rheumatology, University Hospitals Leuven, Leuven, Belgium; IQ Healthcare, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; Division of Orthopedics and Traumatology, Department of Development and Regeneration, University Hospitals Leuven; Physical Medicine and Rehabilitation, University Hospitals Leuven, Pellenberg; and Department of Rehabilitation Sciences, KU Leuven, Heverlee, Belgium. J. Bellemans has previously received institutional support from Smith and Nephew, Biomet, Zimmer, Sanofi Aventis, Technische Orthopedie Belgie, and Pfizer; G. Claes has been involved in studies sponsored by Bayer, Pfizer, BMS, Sanofi-Aventis, ThromboGenics, and Smith-Nephew; and is a former or current member of the advisory boards of Bayer, Pfizer, and Sanofi-Aventis. L. Grypdonck, MD; B. Aertgeerts, MD, PhD, Academic Center for General Practice, KU Leuven; F. Luyten, MD, PhD, Division of Rheumatology, University Hospitals Leuven; H. Wollersheim, MD, PhD, Academic Center for General Practice, KU Leuven; IQ Healthcare, Radboud University Nijmegen Medical Centre; J. Bellemans, MD, PhD, Division of Orthopedics and Traumatology, Department of Development and Regeneration, University Hospitals Leuven; K. Peers, MD, PhD, Physical Medicine and Rehabilitation, University Hospitals Leuven; S. Verschueren, PT, PhD, Department of Rehabilitation Sciences, KU Leuven; P. Vankrunkelsven, MD, PhD, Academic Center for General Practice, KU Leuven; R. Hermens, PhD, Academic Center for General Practice, KU Leuven and IQ Healthcare, Radboud University Nijmegen Medical Centre. Address correspondence to Dr. L. Grypdonck, Academic Center for General Practice, KU Leuven, Kapucijnenvoer 33, blok J, 3000 Leuven, Belgium. E-mail: lies.grypdonck@med.kuleuven.be. Accepted for publication January 11, 2014.
Koen Peers
From the Academic Center for General Practice, KU Leuven, Leuven; Division of Rheumatology, University Hospitals Leuven, Leuven, Belgium; IQ Healthcare, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; Division of Orthopedics and Traumatology, Department of Development and Regeneration, University Hospitals Leuven; Physical Medicine and Rehabilitation, University Hospitals Leuven, Pellenberg; and Department of Rehabilitation Sciences, KU Leuven, Heverlee, Belgium. J. Bellemans has previously received institutional support from Smith and Nephew, Biomet, Zimmer, Sanofi Aventis, Technische Orthopedie Belgie, and Pfizer; G. Claes has been involved in studies sponsored by Bayer, Pfizer, BMS, Sanofi-Aventis, ThromboGenics, and Smith-Nephew; and is a former or current member of the advisory boards of Bayer, Pfizer, and Sanofi-Aventis. L. Grypdonck, MD; B. Aertgeerts, MD, PhD, Academic Center for General Practice, KU Leuven; F. Luyten, MD, PhD, Division of Rheumatology, University Hospitals Leuven; H. Wollersheim, MD, PhD, Academic Center for General Practice, KU Leuven; IQ Healthcare, Radboud University Nijmegen Medical Centre; J. Bellemans, MD, PhD, Division of Orthopedics and Traumatology, Department of Development and Regeneration, University Hospitals Leuven; K. Peers, MD, PhD, Physical Medicine and Rehabilitation, University Hospitals Leuven; S. Verschueren, PT, PhD, Department of Rehabilitation Sciences, KU Leuven; P. Vankrunkelsven, MD, PhD, Academic Center for General Practice, KU Leuven; R. Hermens, PhD, Academic Center for General Practice, KU Leuven and IQ Healthcare, Radboud University Nijmegen Medical Centre. Address correspondence to Dr. L. Grypdonck, Academic Center for General Practice, KU Leuven, Kapucijnenvoer 33, blok J, 3000 Leuven, Belgium. E-mail: lies.grypdonck@med.kuleuven.be. Accepted for publication January 11, 2014.
Sabine Verschueren
From the Academic Center for General Practice, KU Leuven, Leuven; Division of Rheumatology, University Hospitals Leuven, Leuven, Belgium; IQ Healthcare, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; Division of Orthopedics and Traumatology, Department of Development and Regeneration, University Hospitals Leuven; Physical Medicine and Rehabilitation, University Hospitals Leuven, Pellenberg; and Department of Rehabilitation Sciences, KU Leuven, Heverlee, Belgium. J. Bellemans has previously received institutional support from Smith and Nephew, Biomet, Zimmer, Sanofi Aventis, Technische Orthopedie Belgie, and Pfizer; G. Claes has been involved in studies sponsored by Bayer, Pfizer, BMS, Sanofi-Aventis, ThromboGenics, and Smith-Nephew; and is a former or current member of the advisory boards of Bayer, Pfizer, and Sanofi-Aventis. L. Grypdonck, MD; B. Aertgeerts, MD, PhD, Academic Center for General Practice, KU Leuven; F. Luyten, MD, PhD, Division of Rheumatology, University Hospitals Leuven; H. Wollersheim, MD, PhD, Academic Center for General Practice, KU Leuven; IQ Healthcare, Radboud University Nijmegen Medical Centre; J. Bellemans, MD, PhD, Division of Orthopedics and Traumatology, Department of Development and Regeneration, University Hospitals Leuven; K. Peers, MD, PhD, Physical Medicine and Rehabilitation, University Hospitals Leuven; S. Verschueren, PT, PhD, Department of Rehabilitation Sciences, KU Leuven; P. Vankrunkelsven, MD, PhD, Academic Center for General Practice, KU Leuven; R. Hermens, PhD, Academic Center for General Practice, KU Leuven and IQ Healthcare, Radboud University Nijmegen Medical Centre. Address correspondence to Dr. L. Grypdonck, Academic Center for General Practice, KU Leuven, Kapucijnenvoer 33, blok J, 3000 Leuven, Belgium. E-mail: lies.grypdonck@med.kuleuven.be. Accepted for publication January 11, 2014.
Patrik Vankrunkelsven
From the Academic Center for General Practice, KU Leuven, Leuven; Division of Rheumatology, University Hospitals Leuven, Leuven, Belgium; IQ Healthcare, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; Division of Orthopedics and Traumatology, Department of Development and Regeneration, University Hospitals Leuven; Physical Medicine and Rehabilitation, University Hospitals Leuven, Pellenberg; and Department of Rehabilitation Sciences, KU Leuven, Heverlee, Belgium. J. Bellemans has previously received institutional support from Smith and Nephew, Biomet, Zimmer, Sanofi Aventis, Technische Orthopedie Belgie, and Pfizer; G. Claes has been involved in studies sponsored by Bayer, Pfizer, BMS, Sanofi-Aventis, ThromboGenics, and Smith-Nephew; and is a former or current member of the advisory boards of Bayer, Pfizer, and Sanofi-Aventis. L. Grypdonck, MD; B. Aertgeerts, MD, PhD, Academic Center for General Practice, KU Leuven; F. Luyten, MD, PhD, Division of Rheumatology, University Hospitals Leuven; H. Wollersheim, MD, PhD, Academic Center for General Practice, KU Leuven; IQ Healthcare, Radboud University Nijmegen Medical Centre; J. Bellemans, MD, PhD, Division of Orthopedics and Traumatology, Department of Development and Regeneration, University Hospitals Leuven; K. Peers, MD, PhD, Physical Medicine and Rehabilitation, University Hospitals Leuven; S. Verschueren, PT, PhD, Department of Rehabilitation Sciences, KU Leuven; P. Vankrunkelsven, MD, PhD, Academic Center for General Practice, KU Leuven; R. Hermens, PhD, Academic Center for General Practice, KU Leuven and IQ Healthcare, Radboud University Nijmegen Medical Centre. Address correspondence to Dr. L. Grypdonck, Academic Center for General Practice, KU Leuven, Kapucijnenvoer 33, blok J, 3000 Leuven, Belgium. E-mail: lies.grypdonck@med.kuleuven.be. Accepted for publication January 11, 2014.
Rosella Hermens
From the Academic Center for General Practice, KU Leuven, Leuven; Division of Rheumatology, University Hospitals Leuven, Leuven, Belgium; IQ Healthcare, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; Division of Orthopedics and Traumatology, Department of Development and Regeneration, University Hospitals Leuven; Physical Medicine and Rehabilitation, University Hospitals Leuven, Pellenberg; and Department of Rehabilitation Sciences, KU Leuven, Heverlee, Belgium. J. Bellemans has previously received institutional support from Smith and Nephew, Biomet, Zimmer, Sanofi Aventis, Technische Orthopedie Belgie, and Pfizer; G. Claes has been involved in studies sponsored by Bayer, Pfizer, BMS, Sanofi-Aventis, ThromboGenics, and Smith-Nephew; and is a former or current member of the advisory boards of Bayer, Pfizer, and Sanofi-Aventis. L. Grypdonck, MD; B. Aertgeerts, MD, PhD, Academic Center for General Practice, KU Leuven; F. Luyten, MD, PhD, Division of Rheumatology, University Hospitals Leuven; H. Wollersheim, MD, PhD, Academic Center for General Practice, KU Leuven; IQ Healthcare, Radboud University Nijmegen Medical Centre; J. Bellemans, MD, PhD, Division of Orthopedics and Traumatology, Department of Development and Regeneration, University Hospitals Leuven; K. Peers, MD, PhD, Physical Medicine and Rehabilitation, University Hospitals Leuven; S. Verschueren, PT, PhD, Department of Rehabilitation Sciences, KU Leuven; P. Vankrunkelsven, MD, PhD, Academic Center for General Practice, KU Leuven; R. Hermens, PhD, Academic Center for General Practice, KU Leuven and IQ Healthcare, Radboud University Nijmegen Medical Centre. Address correspondence to Dr. L. Grypdonck, Academic Center for General Practice, KU Leuven, Kapucijnenvoer 33, blok J, 3000 Leuven, Belgium. E-mail: lies.grypdonck@med.kuleuven.be. Accepted for publication January 11, 2014.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Development of Quality Indicators for an Integrated Approach of Knee Osteoarthritis
Lies Grypdonck, Bert Aertgeerts, Frank Luyten, Hub Wollersheim, Johan Bellemans, Koen Peers, Sabine Verschueren, Patrik Vankrunkelsven, Rosella Hermens
The Journal of Rheumatology Apr 2014, jrheum.130680; DOI: 10.3899/jrheum.130680
Development of Quality Indicators for an Integrated Approach of Knee Osteoarthritis
Lies Grypdonck, Bert Aertgeerts, Frank Luyten, Hub Wollersheim, Johan Bellemans, Koen Peers, Sabine Verschueren, Patrik Vankrunkelsven, Rosella Hermens
The Journal of Rheumatology Apr 2014, jrheum.130680; DOI: 10.3899/jrheum.130680